MFMelissa F. Fogarty

Melissa F. Fogarty

*This is an algorithmically generated author record based on publicly available information.

Melissa F. Fogarty has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Toxicological evaluation, postmortem case descriptions, and pharmacological activity of N,N-dimethylpentylone and related analogs

    by Melissa F Fogarty, Sara E Walton, Michael T Truver, Grant C Glatfelter, Alex J Krotulski, Donna M Papsun, Michael Lamb, Chris W Chronister, Bruce A Goldberger, Donna Walther, et al.

    Identification of N,N-dimethylpentylone (DMP) in counterfeit “Ecstasy” and “Molly” tablets poses risk to public health due to its adverse effects. Little information is available regarding the pharmacological activity or relevant blood or tissue concentrations of DMP, and even less is known about other structurally related beta-keto methylenedioxyamphetamine analogs on recreational drug markets, such as N-propyl butylone. Here, a novel toxicological assay utilizing liquid chromatography–tandem quadrupole mass spectrometry was developed and validated for the quantitation of DMP and five related synthetic cathinones [eutylone, pentylone, N-ethyl pentylone (NEP), N-propyl butylone, and N-cyclohexyl butylone], with chromatographic resolution from isomeric variants and quantitation performed by standard addition. A forensic series of 125 cases is presented for DMP and related analogs, along with pharmacological activity assessments using monoamine transporter and mouse behavioral assays. The blood concentration range for DMP in postmortem forensic cases was 3.3–4600 ng/mL (mean: 320 ± 570 ng/mL, median: 150 ng/mL), whereas pentylone, the primary N-desmethyl metabolite of DMP, was identified in 98% of cases with a concentration range 1.3–710 ng/mL (mean ± SD: 105 ± 120 ng/mL, median: 71 ng/mL). N-Propyl butylone, a newly identified synthetic cathinone, was quantitated in seven cases (mean ± SD: 82 ± 75 ng/mL, median: 50 ng/mL, range: 1.7–200 ng/mL). DMP displayed potent uptake inhibition at the dopamine transporter [half maximal inhibitory concentration (IC50) of 49 nM], with 100-fold weaker potency at the serotonin transporter (IC50 = 4990 nM). DMP was a locomotor stimulant in mice [medium effective dose (ED50) of 3.5 mg/kg] exhibiting potency relatively similar to eutylone, NEP, and pentylone. Our results show that DMP is a psychomotor stimulant associated with adverse clinical outcomes leading to death. Forensic laboratories must continue to update testing methods to capture emerging drugs, with specific emphasis on resolution and identification of isomeric species. Following the scheduling of DMP in early 2024, there could be an anticipated market shift toward a new unregulated synthetic stimulant to replace DMP.


  • Four-year evaluation of drug-impaired driving drug concentrations

    by Grace Cieri, Amanda L.A Mohr, Melissa Fogarty, Aya Chan-Hosokawa, Barry K Logan

    Drug-impaired driving is a significant public health and safety concern in the USA. To help assess current patterns of drug use in drivers, we evaluated 4 years of drug positivity in a large cohort of suspected impaired drivers. Samples collected between January 2017 and December 2020 were tested via a method compliant with the National Safety Council’s Alcohol, Drugs, and Impairment Division’s Tier I scope of recommended drugs. In 2017, NMS Labs received 17 346 driving under the influence of drugs cases, 17 471 in 2018, 19 050 in 2019, and 16 539 in 2020. The most common drug class detected was cannabinoids in ∼50% of the cases each year. The most common drugs detected over the 4 years were delta-9 tetrahydrocannabinol (delta-9 THC), ethanol, amphetamine/methamphetamine, fentanyl, and alprazolam. Delta-9 THC increased in positivity over the study, having been identified in 45% of cases in 2017, 46% in 2018, 46% in 2019, and 49% in 2020. Ethanol was found in 59% of cases in 2017, 59% in 2018, 61% in 2019, and 53% in 2020. Delta-9 THC and ethanol were the most common drug combination, found together in ∼19% of the cases every year of the study. Statistically significant increases in the average concentration of the following drugs were observed: fentanyl (5.7 ng/mL in 2017 to 9.6 ng/mL in 2020), methamphetamine (301 ng/mL in 2017 to 381 ng/mL in 2020), and delta-9-THC (6.4 ng/mL in 2017 to 7.3 ng/mL in 2020). Other findings included increases in the maximum reported concentrations between 2017 and 2020 for amphetamine (1400 to 2700 ng/mL), methamphetamine (5550 to 13 000 ng/mL), and fentanyl (56 to 310 ng/mL). Statistically significant concentration decreases were noted for several central nervous system depressants, notably prescription benzodiazepines, and several prescription narcotic analgesics.


  • N,N-Dimethylpentylone (dipentylone)—A new synthetic cathinone identified in a postmortem forensic toxicology case series

    by Melissa F Fogarty, Alex J Krotulski, Donna M Papsun, Sara E Walton, Michael Lamb, Michael T Truver, Chris W Chronister, Bruce A Goldberger, Barry K Logan

    Synthetic cathinones emerged on the novel psychoactive substance (NPS) drug market as alternatives to controlled stimulants and entactogens such as methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA). The majority of synthetic cathinones can be subclassified into two groups: beta-keto amphetamines (i.e., NPS with the suffix “drone”) and beta-keto methylenedioxyamphetamines (i.e., NPS with the suffix “lone”). Although a significant number of beta-keto amphetamines have been identified, beta-keto methylenedioxyamphetamines have dominated the NPS market, including notable drugs like methylone, butylone, N-ethyl pentylone (ephylone), eutylone, and now N, N-dimethylpentylone. N, N-Dimethylpentylone, also known as dipentylone or bk-DMBDP, emerged into the illicit drug supply within two months of the international control of eutylone (September 2021). A novel standard addition method was developed and validated for N, N-dimethylpentylone, pentylone, and eutylone, and 18 postmortem cases were quantitated using the method described in this manuscript. The resulting blood concentration range for N, N-dimethylpentylone in this case series was 3.3 to 970 ng/mL (median: 145 ng/mL, mean: 277 ± 283 ng/mL). Pentylone, a metabolite of N, N-dimethylpentylone, was detected in all cases (range: 1.3–420 ng/mL, median: 31 ng/mL, and mean: 88 ± 127 ng/mL). Due to the rise in identifications of N, N-dimethylpentylone in postmortem investigations as well as the potential misidentification of N, N-dimethylpentylone as N-ethyl pentylone, samples testing positive for pentylone should be additionally confirmed for the presence of N, N-dimethylpentylone. Based on prior trends of new synthetic cathinones, it can be theorized that N, N-dimethylpentylone may predominate the U.S. synthetic stimulant market for the next one to two years, however; given the emergence of additional closely related isomeric compounds, it is important to utilize methodology capable of differentiating N, N-dimethylpentylone from its isomers (N-isopropylbutylone, N-ethyl pentylone, N-ethyl N-methyl butylone, hexylone, N-propylbutylone, diethylone, and tertylone).


  • Open Access

    Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review

    by Amanda L A Mohr, Barry K Logan, Melissa F Fogarty, Alex J Krotulski, Donna M Papsun, Sherri L Kacinko, Marilyn A Huestis, Jeri D Ropero-Miller

    An important role of modern forensic and clinical toxicologists is to monitor the adverse events of novel psychoactive substances (NPS). Following a prior review from 2013 to 2016, this critical literature review analyzes and evaluates published case reports for NPS from January 2017 through December 2020. The primary objective of this study is to assist in the assessment and interpretation of these cases as well as provide references for confirmation methods. Chemistry, pharmacology, adverse events and user profiles (e.g., polypharmacy) for NPS are provided including case history, clinical symptoms, autopsy findings and analytical results. Literature reviews were performed in PubMed and Google Scholar for publications using search terms such as NPS specific names, general terms (e.g., ‘designer drugs’ and ‘novel psychoactive substances’), drug classes (e.g., ‘designer stimulants’) and outcome-based terms (e.g., ‘overdose’ and ‘death’). Government and website drug surveillance databases and abstracts published by professional forensic science organizations were also searched. Toxicological data and detailed case information were extracted, tabulated, analyzed and organized by drug category. Case reports included overdose fatalities (378 cases), clinical treatment and hospitalization (771 cases) and driving under the influence of drugs (170 cases) for a total of 1,319 cases providing details of adverse events associated with NPS. Confirmed adverse events with associated toxidromes of more than 60 NPS were reported including synthetic cannabinoid, NPS stimulant, NPS hallucinogen, NPS benzodiazepine and NPS opioid cases. Fifty of these NPS were reported for the first time in January 2017 through December 2020 as compared to the previous 4 years surveyed. This study provides insight and context of case findings described in the literature and in digital government surveillance databases and websites during a recent 4-year period. This review will increase the awareness of adverse events associated with NPS use to better characterize international emerging drug threats.


  • Toxicological and pharmacological characterization of novel cinnamylpiperazine synthetic opioids in humans and in vitro including 2-methyl AP-237 and AP-238

    by Melissa F. Fogarty, Marthe M. Vandeputte, Alex J. Krotulski, Donna Papsun, Sara E. Walton, Christophe P. Stove, Barry K. Logan

    The recent scheduling actions of fentanyl-related substances in both the United States and China have sparked the emergence and proliferation of other generations of “legal” opioids that are structurally distinct from fentanyl, including the recently emerged class of cinnamylpiperazines. In contrast to fentanyl, which contains a piperidine core and a phenethyl moiety, the primary structural components of cinnamylpiperazines are the piperazine core and a cinnamyl moiety. This manuscript reports on the toxicological profile for antemortem and postmortem cases where a cinnamylpiperazine was detected. Samples were quantitatively confirmed using liquid chromatography tandem mass spectrometry. The cases were received between February 2020 and April 2021. Concentrations of 2-methyl AP-237 from four postmortem cases ranged from 820 to 5800 ng/mL, and concentrations of AP-238 from two postmortem cases were 87 and 120 ng/mL. µ-Opioid receptor (MOR) activation potential for 2-methyl AP-237, AP-237, para-methyl AP-237, and AP-238 were studied using a βarr2 recruitment assay. Efficacies (Emax, relative to hydromorphone) and potencies (EC50) were derived and of the compounds tested AP-238 was the most potent compound in the panel with an EC50 of 248 nM. 2-Methyl AP-237 was found to be the most efficacious drug (Emax = 125%) of the tested cinnamylpiperazines; however, it had substantially less efficacy than fentanyl. The in vitro MOR activation potential of the studied cinnamylpiperazines was lower than that of fentanyl and other novel synthetic opioids (NSOs), in line with the relatively higher concentrations observed in postmortem toxicology samples—an important observational link between in vitro pharmacology and in vivo toxicology.


  • Analysis of the Illicit Opioid U-48800 and Related Compounds by LC–MS-MS and Case Series of Fatalities Involving U-48800

    by Melissa F Fogarty, Amanda L A Mohr, Donna M Papsun, Barry K Logan

    We report a method for the detection and quantitation of twelve drugs and two metabolites in the same structural class as the illicit mu-opioid agonist U-47700 in human whole blood. These substances are either known or suspected to be present as potential novel opioids in illicit drug markets. The general class of these drugs was developed in pharmaceutical research programs in the 1970’s but have recently become of concern for overdoses and death in opioid users in the United States and internationally. The scope of analysis included the following compounds: methylenedioxy U-47700, ethylenedioxy U-47700, ethylenedioxy U-51754, U-69593, U-47931E (Bromadoline), U-47700, U-48800, U-49900, U-51754, U-50488, propyl U-47700, and isopropyl U-47700. Additionally, two metabolites, N,N-didesmethyl U-47700, desmethyl U-47700 were also included in the scope. Drugs were extracted from human whole blood using solid phase extraction (SPE) and the extracts were analyzed by liquid chromatography tandem mass spectrometry (LCMSMS). The assay was validated with respect to bias, carryover, interference, and within run and between run precision, and accuracy. Eight medicolegal death investigation cases which had screened positive for U-48800 by liquid chromatography time-of-flight mass spectrometry (LCTOF) were successfully confirmed and quantified using this method. The mean and median concentrations of U-48800 in these cases were 2.5 (±2.1) ng/mL and 1.8 ng/mL, respectively, with a range of concentrations of 0.27-6.2 ng/mL. Case history information including the presence of other drugs in combination are described and discussed.


  • Open Access

    U-47700 and Its Analogs: Non-Fentanyl Synthetic Opioids Impacting the Recreational Drug Market

    by Michael H. Baumann, Graziella Tocco, Donna M. Papsun, Amanda L. Mohr, Melissa F. Fogarty, Alex J. Krotulski

    The recreational use of opioid drugs is a global threat to public health and safety. In particular, an epidemic of opioid overdose fatalities is being driven by illicitly manufactured fentanyl, while novel synthetic opioids (NSOs) are appearing on recreational drug markets as standalone products, adulterants in heroin, or ingredients in counterfeit drug preparations. Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) is a prime example of a non-fentanyl NSO that is associated with numerous intoxications and fatalities. Here, we review the medicinal chemistry, preclinical pharmacology, clandestine availability, methods for detection, and forensic toxicology of U-47700 and its analogs. An up-to-date summary of the human cases involving U-47700 intoxication and death are described. The evidence demonstrates that U-47700 is a potent μ-opioid receptor agonist, which poses a serious risk for overdosing and death. However, most analogs of U-47700 appear to be less potent and have been detected infrequently in forensic specimens. U-47700 represents a classic example of how chemical entities from the medicinal chemistry or patent literature can be diverted for use in recreational drug markets. Lessons learned from the experiences with U-47700 can inform scientists, clinicians, and policymakers who are involved with responding to the spread and impact of NSOs.


  • Letter to Editor—NBOH Derivatization for the Analysis of Seized Drug Casework by GC‐MS

    by Melissa F. Fogarty, Barry K. Logan, Francis X. Diamond, Lynsey Mickolas, Sarah A. Shuda, Alex J. Krotulski


  • Analysis of cis and trans 3‐methylfentanyl by liquid chromatography–high resolution mass spectrometry and findings in forensic toxicology casework

    by Melissa F. Fogarty, Donna M. Papsun, Barry K. Logan

    3‐methylfentanyl (3‐MF), N‐(3‐methyl‐1‐phenethyl‐4‐piperidyl)‐N‐phenyl‐propanamide, has reappeared on the US illicit drug market since its disappearance after a series of overdose deaths in 1988. 3‐MF presents an analytical challenge, due to presence of cis and trans stereoisomers, each with different potencies, and ultimately very low concentrations in the blood after use. A method was developed using liquid chromatography–time‐of‐flight–mass spectrometry for the analysis of (±)‐cis‐3‐MF and (±)‐trans‐3‐MF in blood specimens after solid phase extraction. The linear dynamic range of this method was 0.1–10 ng/mL. Blood samples from 25 postmortem cases and 2 human performance case involving 3‐MF were submitted for quantitative analysis. The mean and median concentration for the (±)‐cis‐3‐MF were 0.84 ng/mL (±0.81) and 0.67 ng/mL, respectively, range 0.14–3.43 ng/mL. The resulting (±)‐trans‐3‐MF mean concentration was 0.46 ng/mL (±0.38) and the median concentration was 0.37 ng/mL with a range of 0.11–1.90 ng/mL. The resulting (±)‐cis‐3‐MF and (±)‐trans‐3‐MF concentrations were summed to give the total amount of 3‐MF present in the case with the resulting average concentration at 1.28 ng/mL (±1.16), median at 1.01 ng/mL and range 0.18–5.18. As the estimated dose of this compound is approximately 0.1 mg–0.5 mg with the resulting concentrations in the sub‐nanogram range, it is necessary for forensic toxicology laboratories to obtain instruments sensitive enough to detect these substances in driving under the influence of drugs and postmortem cases. Quantitation of 3‐MF with separation of (±)‐cis and (±)‐trans‐3‐MF provides additional detail for more specific toxicological interpretation.